TESSP2 Inhibitors
Chemical inhibitors of TESSP2 can affect its activity through various mechanisms involving the interruption of signal transduction pathways. Wortmannin and LY294002 are potent inhibitors of the PI3K/AKT pathway, a crucial signaling mechanism that TESSP2 may rely on for proper function. By inhibiting PI3K, these chemicals can prevent the activation of AKT, a kinase that phosphorylates a wide array of substrates, potentially including TESSP2 or its partners. This inhibition effectively halts the propagation of signals necessary for TESSP2's functions, resulting in its functional inhibition. Rapamycin, acting downstream, specifically inhibits the mTOR pathway, which is intricately connected to the PI3K/AKT pathway. The inhibition of mTOR by Rapamycin could disrupt TESSP2's involvement in processes regulated by mTOR, such as protein synthesis and cell proliferation, leading to a decrease in TESSP2's functional activity.
Further targeting different aspects of cellular signaling, PD98059 and U0126 function as MEK inhibitors. These inhibitors block the activation of the MEK/ERK pathway, which TESSP2 might utilize. The prevention of ERK activation by these chemicals means that any roles TESSP2 plays in response to ERK-mediated signals would be suppressed. The p38 MAP kinase is another target, with SB203580 impeding its activity. As p38 MAPK is involved in stress responses and cytokine production, the inhibition of this kinase by SB203580 can lead to a reduction in TESSP2's role in these responses. Similarly, SP600125 inhibits the JNK pathway, a signaling route that can modulate TESSP2's function by altering the phosphorylation state of proteins in the pathway. Src family kinases, targeted by the inhibitor PP2, and broad-spectrum kinase activities, including Src family kinases affected by Dasatinib, are essential for multiple phosphorylation events. Inhibition of these kinases can prevent TESSP2 from achieving its active state. Lastly, Imatinib, Erlotinib, and Sorafenib target specific tyrosine kinases such as ABL, EGFR, and RAF, respectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor which would inhibit the PI3K/AKT pathway. Since TESSP2 is involved in cell signaling, its inhibition could result in the functional inhibition of TESSP2 by preventing downstream signaling necessary for TESSP2's role in cellular processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin, it inhibits the PI3K/AKT pathway. The inhibition of this pathway can lead to a reduction in phosphorylation events that TESSP2 requires for its activity, thus functionally inhibiting TESSP2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that directly inhibits the mTOR pathway which is downstream of PI3K/AKT. By inhibiting mTOR, Rapamycin can disrupt the processes that TESSP2 is involved in, such as cell growth and proliferation, leading to functional inhibition of TESSP2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor which would target the MEK/ERK pathway, a pathway that TESSP2 could be involved in. By inhibiting MEK, PD98059 can prevent the activation of ERK which would subsequently inhibit the phosphorylation and activity of TESSP2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor, functioning similarly to PD98059 to inhibit the MEK/ERK pathway. The inhibition of this pathway would lead to a decrease in ERK-mediated phosphorylation events that are crucial for the functional activity of TESSP2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, and inhibition of p38 MAPK can affect the signaling pathways that TESSP2 is a part of. This can lead to functional inhibition of TESSP2 by hindering the cellular responses it mediates, such as stress response and cytokine production. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK pathway, which may be involved in the signaling processes of TESSP2. By inhibiting JNK, SP600125 can prevent the phosphorylation of substrates involved in TESSP2's pathway, leading to functional inhibition of the protein's activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can phosphorylate substrates that TESSP2 might act upon or be regulated by. Inhibition of Src family kinases can thus prevent TESSP2 from exerting its activity, leading to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that would inhibit Src family kinases among others. By inhibiting these kinases, Dasatinib can disrupt the phosphorylation and activation of TESSP2, leading to its functional inhibition. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that can inhibit the ABL kinase. ABL kinase is involved in various signaling pathways that could intersect with TESSP2's activity. Inhibition of ABL kinase can therefore lead to functional inhibition of TESSP2 by blocking its activation and function. | ||||||